Last reviewed · How we verify

NCT05075005

The Effects of Terrain Variation on Intrinsic Foot Musculature in Healthy Individuals and Individuals With Plantar Fasciitis

Recruiting now NA Last updated 28 August 2025
What this trial tests

NA trial testing Treatment Cohort in Plantar Fasciitis in 60 participants. Currently enrolling.

Timeline
15 July 2022
Primary endpoint
20 August 2026
20 August 2026

Quick facts

Lead sponsorUniversity of Florida
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date15 July 2022
Primary completion20 August 2026
Estimated completion20 August 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Florida

Who can join

Adults 18 to 100, any sex, with Plantar Fasciitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Modern footwear has been implicated as a contributor to foot pathology and changes in the biomechanics of gait. In addition to footwear, the investigators propose that the lack of terrain variation may directly contribute to the development of common foot pathologies, resulting from decreased intrinsic foot muscle function. This study will examine the current understanding of terrain variation on foot musculature strength and its possible correlation with structural and functional changes within the foot.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Plantar Fasciitis

Currently open trials in the same condition.

Other University of Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05075005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing